The program times are listed in Central European Time (CEST)
BAQSIMI and Diabetes Technology: Where Do They Fit into Total Patient Care? - Industry Symposium Supported by Eli Lilly
Session description -Welcome to BAQSIMI® (glucagon) nasal powder 3mg and Diabetes Technology: Where Do They Fit Into Total Patient Care? presented by Tadej Battelino, MD, PhD, and Marga Giménez, MD, PhD. During this symposium presentation, we will discuss how diabetes technology, hypoglycaemia, and BAQSIMI are connected within total patient care. We will share information about BAQSIMI - the first and only glucagon with nasal administration - including product attributes, clinical data, and product use and administration. In addition, we will highlight the importance of preparing people with diabetes, and those around them, for severe hypoglycaemia rescue—just in case. Thank you for joining us!
The materials for Baqsimi® (glucagon) nasal powder 3mg contained in this virtual symposium are approved following the Summary of Product Characteristics (SPC). Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).